To the best of our knowledge, this report is the first to use CGM data in patients with T2D to study and compare the effects of RHI with those of a rapid-acting insulin analog, whether administered by MDIs or by a novel IDD. This evidence concerns the gene INS and type 2 diabetes mellitus.